Q-omics provides the consensus-scored MFSD8 profile across patient tissues and cancer cell-line models. MFSD8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MFSD8 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, MFSD8 RNA expression shows 21,166 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where MFSD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD8 survival associations across molecular data types. MFSD8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD8 RNA expression–survival associations across cancer types. High MFSD8 expression shows unfavorable associations in UVM and LGG, but favorable associations in KIRC, LUAD, BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MFSD8 RNA expression.
This table summarizes MFSD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MFSD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD8 shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, LIHC, CHOL and HNSC. The THCA box plot shows higher MFSD8 RNA expression in normal versus tumor tissue (log2 FC = −0.431, t-test p < 0.001).
This table shows molecular features associated with MFSD8 in patient tissues and cancer cell lines. In patient samples, MFSD8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
